5Y Capital

5Y Capital, previously known as Morningside Venture Capital, is a private equity and venture capital firm based in Shanghai, China, with additional offices in Beijing and Hong Kong. Founded in 1992, it specializes in early-stage investments across a wide range of sectors, including healthcare, technology, fintech, consumer services, media, and education. The firm manages approximately USD 3 billion in funds, leveraging investments from prominent sovereign wealth funds, family offices, and other institutional investors. With an initial investment threshold of over USD 500,000 per portfolio company, 5Y Capital focuses primarily on opportunities in China and other emerging markets in Asia and the Pacific. It is a subsidiary of the Morningside Group, which has a long-standing commitment to socially responsible investing and philanthropic initiatives, particularly in education and scientific research.

W. Anthony Brooke

Director

Zhe Chen

Managing Director

Yu Cheng

Partner

Ziyou Fu

Investor Relations Professional

Hanson Hu

Investment Manager

Lu Huang

Managing Director

Levi Liu Kai

Partner

Yantao Lai

Investment Manager

Tony Lian

Investment Manager

Wentian Lian

VP

Richard Liu

Founding Partner

Qin Liu

Co-Founding Partner

Sylvia Liu

Investment Manager

Weimin Luo

Partner and Senior Consultant

Jianming Shi

Director of Business Development

Kejia Tang

Human Resource Director

Ji Tong

Investment Manager

Sixue Wang

Public Relations and Investor Relations Professional

Qiong Xue

CFO

Dan You

Executive Director

Ye Yuan

Partner

Bo Zhang

Managing Director

Oliver Zhang

Investment Manager

Fei Zhang

Partner

860 past transactions

PhoreMost

Private Placement in 2018
PhoreMost Limited, a drug discovery company, engages in identifying new druggable targets for cancer and other unmet diseases. It develops Site-Seeker, a platform that systematically unmasks druggable sites in the human genome and links them to useful therapeutic functions in a live-cell context. The company was incorporated in 2014 and is based in Cambridge, United Kingdom.

Phynova China Limited

Phynova China Limited engages in the marketing and distribution of pharmaceuticals derived from Chinese botanical drugs for the treatment of viral and metabolic diseases and cancer in China. The company was founded in 2006 and is based in Hong Kong. Phynova China Limited operates as a subsidiary of Phynova Group PLC.
Drug discovery inspired by viruses

Taimei Technology

Private Placement in 2019
Taimei Technology provides a cloud platform for clinical research collaboration. It is dedicated to propelling biopharmaceutical industry development through technology with a focus in the field of clinical research and pharmacovigilance. Taimei Technology cloud platform was designed for clinical research collaboration between sponsors, sites, CROs, patients, regulatory agencies and third-party providers. Its platform offers 6 technology-enabled solutions encompassing data management, project management, electronic regulatory submission, central medical imaging, pharmacovigilance, and drug logistics. Its clients include pharmaceutical enterprises, CRO and research institutes. The company was founded in 2013 and is headquartered in Jiaxing, Zhejiang, China.
Mohalla Tech Pvt. Ltd. owns and operates social network platform ShareChat. It helps users to create and find content in preferred language and share on mobile messaging platforms. Mohalla Tech Pvt. Ltd. was incorporated in 2015 and is based in Bengaluru, India.

LIZHI INC.

Series C in 2015
Lizhi Inc. operates an online user-generated content audio community, interactive audio entertainment platform, and online audio platform in China. It provides podcasts and audio entertainment products. The company also offers Lizhi app that allows users to record and share their voices on mobile devices. The company has collaboration with Xpeng Motors to integrate its in-car audio content product into Xpeng Motors’ in-car intelligent operating system. Lizhi Inc. was founded in 2010 and is headquartered in Guangzhou, the People’s Republic of China.
ZielBio, Inc., a biotechnology company, identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. The company manufactures a lead compound ZB131, a humanized monoclonal antibody against cell surface plectin (CSP), an identified cancer target, including ovarian, pancreatic, lung and colorectal. Zielfind, a drug discovery platform that combines throughput screening with large content data analytics to identify high value targets. ZielBio, Inc. was formerly known as iTi Health, Inc. The company was founded in 2010 and is based in Charlottesville, Virginia.

Vastai Technologies

Series A in 2020
Vastai Technologies is focused on developing AI chips for the optimization of computer vision and video processing.

XY Mens

Series A in 2016
XY MENS provides Internet retailing services for men's fashion products. Its e-commerce platform offers discount zone, gift area, duty-free import, and other direct entrances for shoes, sheets, skincare products, and bags. The company also offers latest trends guide, clothing tips, and related products guide. The company was founded in 2014 and is headquartered in Beijing, China.

F2G

Venture Round in 2020
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.

Elysium

Series B in 2016
Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs. It seeks to solve challenges in health with science, to help people live healthier and longer lives. It works directly with the scientists, clinicians, and health professionals around the world to identify and develop the natural compounds. Its product is a proprietary formulation of two ingredients designed to support long-term well-being at the cellular level.
Gorilla Technology Group, Inc. offers a platform that combines video analytics and IoT technology to deliver business intelligence insights for improving performance in sales, operations and understanding of customer needs. Its current clients include Shanghai Media Group. Gorilla Technology Group, Inc. was founded in 2001 and is based in Taipei, Taiwan.
OrienGene Biotechnology Ltd. is a drug discovery and development company that focuses on the treatment of cancer. The company is based in Beijing, China.
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Their team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet need their programs seek to address. It was founded in 2007 and headquartered in Newton, Massachusetts.
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Their team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet need their programs seek to address. It was founded in 2007 and headquartered in Newton, Massachusetts.
Meissa Vaccines is a start-up pharmaceutical development company focused on the in-licensing and advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical need in pediatrics) and rhinovirus (leading cause of infectious disease worldwide). Their passion is child health, but our vaccine programs have the potential to benefit multiple age groups directly and indirectly. Successful vaccines for respiratory syncytial virus and rhinovirus would have widespread benefits for society and families. These include reducing the burden of acute lower respiratory tract disease, reducing colds, reducing acute asthma exacerbations caused by these viruses, and alleviating missed school and work.
Shanghai Clarity Machinery Co.,Ltd. designs, manufactures, and distributes printing machinery in China. It offers offset perfectors, gravure presses, offset presses, UV coating machines, trimmers, and film coat presses. The company is based in Shanghai, China.

Redesign Science

Private Placement in 2019
They efficiently simulate protein targets at the atomic level to reveal hidden, subtle drug opportunities that fall outside the capability and scope of alternative computational models.Basic science is proliferating with new understanding of biological pathways and disease mechanisms. New technologies are needed to solve emerging challenges and to commercialize new opportunities.

Liquidia Technologies

Series D in 2018
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
The Edyn smart garden system lets you know what’s happening in your garden at all times. Whether you’re a novice gardener or managing a small-scale organic farm, Edyn is there to take the guesswork out of gardening. Inserted in the soil, the Edyn Garden Sensor gathers and analyzes data about changing weather and soil conditions. The Edyn App displays this data as a real-time snapshot of your garden, and pushes alerts and suggestions to maximize plant health.

Edyn

Seed Round in 2016
The Edyn smart garden system lets you know what’s happening in your garden at all times. Whether you’re a novice gardener or managing a small-scale organic farm, Edyn is there to take the guesswork out of gardening. Inserted in the soil, the Edyn Garden Sensor gathers and analyzes data about changing weather and soil conditions. The Edyn App displays this data as a real-time snapshot of your garden, and pushes alerts and suggestions to maximize plant health.

K-Gen, Inc.

K-Gen, Inc. discovers new inhibitors for K-Ras specific stemness pathways in cancer. The company was incorporated in 2015 and is based in Burlingame, California.

Iwjw

Series A in 2014
Iwjw operates an online platform offering online to offline house rental services. The platform accepts bookings of prospective clients to make ocular visits to houses. Iwjw began operation on March 17, 2014. Its headquarters is in Shanghai in China.

Weiyi Group

Private Placement in 2019
Weiyi Group owns and operates an online platform for hospital appointment registration. It also provides online inquiry, remote consultation, electronic prescription, drug distribution, and medical membership services. The company was formerly known as Guahao.com Limited. Weiyi Group was founded in 2010 and is based in Hangzhou, China.
CrestMarc Woodstock Properties LLC engages in the identification, acquisition, rehabilitation, and disposition of multi-family properties. It also engages in the repositioning, asset management, property management, construction, and development of multi-family properties. CrestMarc Woodstock Properties LLC was founded in 2004 and is based in Dallas, Texas.
Synermore Biologics CO., Ltd provides research and development of biosimilar monoclonal antibodies in the areas of oncology, infectious diseases, and immune disorders. The products include SYN004, recombinant chimeric monoclonal antibody; SYN023, a mixture of two anti-rabies humanized monoclonal antibodies; and SYN008, a biosimilar of Omalizumab. The company was founded in 2013 and is headquartered in Taipei City, Taiwan.
Agora is a high-growth Communications-Platform-as-a-Service (CPaaS) provider delivering mobile-first, real-time communications for developers and businesses globally. Agora's API is the most widely adopted API for real-time communications around the world, installed on more than 500 million devices and rapidly growing. The Agora real-time communication stack includes features like include voice calling, video calling, group conferencing, interactive broadcasting, and much more. Reliable, accessible and scalable, Agoria.io provides communications services to organizations across industries, including telemedicine, education, financial services, customer service, social media applications, and mobile gaming.

Xunlei

Series E in 2014
Xunlei Limited operates an Internet platform for digital media content in the People's Republic of China. The company’s platform is based on cloud technology that enables users to access, manage, and consume digital media content. It offers Xunlei Accelerator, which enables users to accelerate digital transmission over the Internet; mobile acceleration plug-in, which provides mobile device users with benefits of download speed acceleration and download success rate improvements; and cloud acceleration subscription services that offer users premium services through various products, such as Green Channel. The company also provides Mobile Xunlei, a mobile application that allows users to search, download, and consume digital media content on their mobile devices; Xunlei Media Player, which supports online and offline play of digital media content, as well as simultaneous play of digital media content while it is being transmitted by Xunlei Accelerator; online games through online game Website and mobile app; live video streaming and online advertising services; and cloud computing and other Internet value-added services. As of December 2019, its platform had approximately 88.3 million monthly unique visitors. The company was formerly known as Giganology Limited and changed its name to Xunlei Limited in January 2011. Xunlei Limited was founded in 2003 and is based in Shenzhen, the People's Republic of China.

Galixir

Seed Round in 2020
Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for the drugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development.
Maiditu Trade and Industry (Shanghai) Co., Ltd. manufactures 3D printing equipment. Its product Meditool, which makes imaging for implants in the field of dentistry, neurosurgery, oral and maxillofacial surgery, and spinal surgery. The company also develops medical imaging data processing software for the health care industry. Maiditu Trade and Industry (Shanghai) Co., Ltd. was founded in 2014 and is based in Shanghai, China.

Traversa Therapeutics, Inc.

Traversa Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of RNAi delivery Technologies. The company’s short interfering RNA (siRNA) platform delivery technologies are used by RNAi therapeutic companies in targeting for the treatment of various acute, chronic, and infectious human diseases. It serves customers in the United States and internationally. The company was founded in 2006 and is based in San Diego, California. As of 2012, Traversa Therapeutics, Inc. is in liquidation.

evonetix

Series B in 2023
evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
Tile Shop Holdings, Inc. operates as a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories in the United States. It offers products, including marble, travertine, granite, quartz, sandstone, slate, and onyx tiles; and ceramic, porcelain, glass, cement, wood look, and metal tiles primarily under the Rush River and Fired Earth brands. The company also manufactures setting and maintenance materials, such as thinset, grout, sealers, and accessories, including installation tools, shower and bath shelves, drains, and similar products under the Superior brand name. As of August 06, 2020, it operated 142 stores in 31 states and the District of Columbia. Tile Shop Holdings, Inc. was founded in 1985 and is headquartered in Plymouth, Minnesota.

Easyhin

Series B in 2016
Easyhin Technology is a combination of cross-border healthcare industry and the Internet industry, is committed to creating a new generation of Internet "health care." Tencent core team in both the products and the technical backbone of Ali, TOP Internet, but also in-depth understanding of Chinese healthcare industry, a senior 500 executives, as well as front-line services in the three large clinical specialist doctors. The company was awarded a top international VC investment, and users of the Internet thinking and ideas to create the best mobile baby health management services platform to mom.

Bombax

Series A in 2021
Xiaoice is an AI company that develops a chatbot that acts as a digital assistant with the capability to understand human conversations. Xiaoice allows cross-platform interactions, enabling users to enjoy the convenience of artificial intelligence. Xiaoice is designed as a teenage girl and is touted as an empathic computing framework focusing on longer back-and-forth conversations with humans instead of simply answering questions or obeying commands like most bots. Its technology covers natural language processing, computer voice, computer vision, and AI content generation.
MaxiNovel Pharmaceuticals, Inc. engages in research, development, and manufacturing of oncology drugs in areas of targeted therapy and immuono-oncology. The company is based in Guangzhou, China with branches in Shanghai, China; Australia; and the United States.

Xunlei

Series B in 2005
Xunlei Limited operates an Internet platform for digital media content in the People's Republic of China. The company’s platform is based on cloud technology that enables users to access, manage, and consume digital media content. It offers Xunlei Accelerator, which enables users to accelerate digital transmission over the Internet; mobile acceleration plug-in, which provides mobile device users with benefits of download speed acceleration and download success rate improvements; and cloud acceleration subscription services that offer users premium services through various products, such as Green Channel. The company also provides Mobile Xunlei, a mobile application that allows users to search, download, and consume digital media content on their mobile devices; Xunlei Media Player, which supports online and offline play of digital media content, as well as simultaneous play of digital media content while it is being transmitted by Xunlei Accelerator; online games through online game Website and mobile app; live video streaming and online advertising services; and cloud computing and other Internet value-added services. As of December 2019, its platform had approximately 88.3 million monthly unique visitors. The company was formerly known as Giganology Limited and changed its name to Xunlei Limited in January 2011. Xunlei Limited was founded in 2003 and is based in Shenzhen, the People's Republic of China.

Alentis Therapeutics

Series B in 2021
Alentis Therapeutics AG develops and manufactures medications to treat advanced liver diseases. It develops medications for liver fibrosis, cirrhosis, and liver cancer. The company was founded in 2019 and is based in Basel, Switzerland.

Xiaomi

Series E in 2014
Xiaomi Inc. manufactures and distributes mobile phones and consumer electronics. The company also develops mobile applications. Xiaomi targets the lower-middle market and has gained a loyal fan base by incorporating user feedback into the design of its latest sets and Android skins. It offers internet value-added products including TV boxes, backpacks, phone screen protectors, earphones, and more. Its products include Redmi, an Android smartphone; MIUI ROM, a customizable ROM; MiTalk, a messaging application; Mi TV, a 3D television; MiBox, a set-top box; MIUI, an operating system; MiWiFi, a network router; MiPower Bank, an external battery; and more. Xiaomi Inc. was founded in April 2010 and is based in Beijing, China.

Hangzhou Bizhi Technology Co., Ltd.

Private Placement in 2020
Hangzhou Bizhi Technology Co., Ltd. is a private company engaged in deep research on big data platforms and development of artificial intelligence. The firm's product relies on Alibaba cloud Infrastructure-as-a-service (IaaS). It was founded on 2016 and is based in Hangzhou, China.

BetterUp

Series E in 2021
Founded in 2013, BetterUp is a mobile-based leadership development platform used by Fortune 500 companies. With a holistic, science-backed methodology, BetterUp develops new behaviors and mindsets that enable high performance amid constant and accelerating change. Through on-demand, virtual coaching sessions, users practice and reinforce new behaviors and skills. Individual growth is measured and tracked. With a diverse range of customers, including Genentech, Logitech, and Workday, BetterUp inspires employees to build the skills to thrive personally and professionally.

AGORAB2B

Series B in 2015
AGORA is a B2B e-commerce platform that offers expertise in the areas of B2B portal development. AGORA helps small and medium scale businesses in monitoring stock availability and goods prices, allowing businesses to make online reservations in the supplier's enterprise resource planning (ERP) software.

Ishen365

Private Placement in 2018
Ishen365 develops and operates renal care service platform for healthcare sector. It provides chronic disease management solutions for patients with kidney disease. The company is based in Shanghai, China.

Advanced Cell Diagnostics

Series B in 2012
Advanced Cell Diagnostics (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.

Yunhu Health

Seed Round in 2017
Hangzhou Yunhu Technology Group Co.,Ltd develops an Internet platform for primary medical services in China. It offers a series of platform-based testing products; and a SaaS based LIS\HIS platform, designed for local medication institutions. It also provides a third party cold chain logistic services to support the blood and drug delivery. The company was founded in 2017 and is based in Hangzhou, China.

Cheyipai

Series A in 2011
Cheyipai is a private company engaged in e-commerce. It provides sells used vehicles online and online-to-offline (O2O) e-commerce model for the complete transaction process. Wang Tiezhong and Yang Xuejian founded Cheyipai in 2009, with its headquarters in Beijing in China. It operates as a subsidiary of Souche.com as of April 3, 2018.

Zilliz

Series B in 2020
Zilliz develops data processing platform. The company also offers artificial intelligence technology and big data technology. The company was founded in 2016 and is based in San Francisco, California.

Procarta Biosystems

Venture Round in 2012
Procarta Biosystems Ltd develops antibacterials through an adaptable DNA-based platform for clinics. It provides snare, a set of proprietary nanoparticles that deliver an oligonucleotide inside the bacterial pathogen, including MRSA snare, a topical and intravenous solution; Broad-spectrum Gram-negative therapy snare, which treats hospital acquired infections; and Cdiff snare, which prevents recurrence of CDI. The company was founded in 2007 and is based in Norwich, United Kingdom.

Lele Ketang

Series C in 2020
LeLe Ketang offers online K-12 education services. The company focuses on primary school math and language. LeLe Ketang was founded in 2014 and is based in Beijing, China.
Ultrain Technology Ltd. develops a decentralized blockchain platform, which is able to control its contract functions with operating system level process management and life circle management. Its platform provides services, which includes high performance computing, value computation, democratic voting system, and user friendly intelligent contract. The company offers a blockchain infrastructure, which includes blockchain consensus algorithm, operation system architect design, edge computation, and blockchain network governance. The company was founded in 2017 and is based in Hangzhou, China.

Amylyx Pharmaceuticals

Private Placement in 2020
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.

Xiaomi

Series C in 2012
Xiaomi Inc. manufactures and distributes mobile phones and consumer electronics. The company also develops mobile applications. Xiaomi targets the lower-middle market and has gained a loyal fan base by incorporating user feedback into the design of its latest sets and Android skins. It offers internet value-added products including TV boxes, backpacks, phone screen protectors, earphones, and more. Its products include Redmi, an Android smartphone; MIUI ROM, a customizable ROM; MiTalk, a messaging application; Mi TV, a 3D television; MiBox, a set-top box; MIUI, an operating system; MiWiFi, a network router; MiPower Bank, an external battery; and more. Xiaomi Inc. was founded in April 2010 and is based in Beijing, China.

Hangzhou Bizhi Technology Co., Ltd.

Private Placement in 2020
Hangzhou Bizhi Technology Co., Ltd. is a private company engaged in deep research on big data platforms and development of artificial intelligence. The firm's product relies on Alibaba cloud Infrastructure-as-a-service (IaaS). It was founded on 2016 and is based in Hangzhou, China.
Matatu operates as a biotech company. The company is based in the United States.
PhoreMost Limited, a drug discovery company, engages in identifying new druggable targets for cancer and other unmet diseases. It develops Site-Seeker, a platform that systematically unmasks druggable sites in the human genome and links them to useful therapeutic functions in a live-cell context. The company was incorporated in 2014 and is based in Cambridge, United Kingdom.

Kuaishou

Series D in 2017
Kuaishou is a photo-sharing app based in China. Kuaishou was founded in 2011 and it began life as a destination for photo sharing on mobile. That side of its business has picked up 400 million users but, like other Chinese tech firms and even Western photo apps like Instagram, it has ventured into live-streaming with some success. Kuaishou claims to have reached 50 million daily users, with five million videos uploaded to its service each day.

Xiaomi

Series A in 2010
Xiaomi Inc. manufactures and distributes mobile phones and consumer electronics. The company also develops mobile applications. Xiaomi targets the lower-middle market and has gained a loyal fan base by incorporating user feedback into the design of its latest sets and Android skins. It offers internet value-added products including TV boxes, backpacks, phone screen protectors, earphones, and more. Its products include Redmi, an Android smartphone; MIUI ROM, a customizable ROM; MiTalk, a messaging application; Mi TV, a 3D television; MiBox, a set-top box; MIUI, an operating system; MiWiFi, a network router; MiPower Bank, an external battery; and more. Xiaomi Inc. was founded in April 2010 and is based in Beijing, China.

Artugen Therapeutics Limited

Artugen Therapeutics Limited researches and develops targeted treatments for bacterial infections. The company was incorporated in 2015 and is based in Dublin, Ireland.

Apellis Pharmaceuticals

Series D in 2016
Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.
Bio-Cancer Treatment International Limited, a clinical-stage biopharmaceutical company, focuses on the research and development of biologics for the treatment of human malignancies and immune disorders. It develops BCT-100-pegylated recombinant human arginase 1, a urea cycle enzyme of 329 amino acid residues for arginine depletion therapy in arginine auxotrophic cancers; and BCT-200, a modification of BCT-100 with alterations to the amino acid sequence for arginine depletion therapy in autoimmune disorders. The company was founded in 2000 and is based in Sha Tin, Hong Kong with an additional office in Shanghai, China.

Shukun Technology

Private Placement in 2019
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.
Retrotope Inc. develops drugs for the treatment of degenerative and intractable diseases. The company develops drugs for the treatment of diseases, such as Parkinson, Alzheimer, mitochondrial myopathies, and retinopathies. It provides RT001, a drug for the treatment of infantile neuroaxonal dystrophy. It also operates an online drug platform to preserve and restore mitochondrial health in degenerative diseases. Retrotope Inc. was incorporated in 2006 and is based in Los Altos, California.

Xbiome

Series B in 2021
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to more quickly develop effective pharmaceuticals.

Musical.ly

Series B in 2015
Founded in 2014, by creator Alex Zhu and longtime friend, Luyu Yang, musical.ly is a video social network for creating, sharing and discovering short videos. Every day, millions of teens use musical.ly as an outlet to express themselves through singing, dancing, comedy, and lip-syncing. The app celebrates creativity with videos recorded in 15 seconds or less that are shared across the musical.ly community. More than half of U.S. teens are users of musical.ly. Since first being made available in October 2014, musical.ly has hit #1 in the iOS App Store for free apps in 20 countries - including the United States. In 2017 Musical.ly was acquired by ByteDance subsidiary Toutiao, and in 2018 Musical.ly was merged into ByteDance subsidiary TikTok.

Haohaozhu

Series A in 2015
Haohaozhu owns and operates an online platform for home improvement. It operates an online platform and a mobile application, which allows users to access the platform to look for decoration solutions that suit their homes and connects them to sellers. The company's platform allows users to share images. The company was founded in 2015 and is based in Beijing, China.
Kuaishou is a photo-sharing app based in China. Kuaishou was founded in 2011 and it began life as a destination for photo sharing on mobile. That side of its business has picked up 400 million users but, like other Chinese tech firms and even Western photo apps like Instagram, it has ventured into live-streaming with some success. Kuaishou claims to have reached 50 million daily users, with five million videos uploaded to its service each day.

Zhongke Guosheng

Angel Round in 2021
Zhongke Guosheng is a bio-based materials R&D firm that designs and develops furan-based bio-based materials.

CellCentric

Private Placement in 2018
CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Arctic Vision

Series B in 2021
Arctic Vision is a China-based clinical-stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company's vision is to address ophthalmology's unmet needs through innovative therapies in China, Asia, and globally. Arctic Vision is established by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products.

Rockley Photonics

Series E in 2019
Rockley Photonics manufactures photonics chips and custom integrated packaged products. It offers products for broad market applications ranging from communications to consumers. The company is focused on sales of chipsets plus the customer-specific design of photonics chips and custom integrated packaged products. In this way, Rockley Photonics leverages its investment in photonics platform research and process development across broader market applications. Rockley Photonics was founded in 2013 and is headquartered in Pasadena, CA.

XYZ Robotics

Private Placement in 2020
XYZ Robotics develops AI-enabled robotic perception and manipulation technology for logistics and manufacturing automation. The company develops autonomous robotic solutions for put wall sorting and goods-to-person picking. Its robot sorts unorganized, random warehouse goods into groups of customer orders. The solution embodies its strength in deep learning and robotics.

Morningside Venture IV Investments Limited

Morningside Venture IV Investments Limited is based in the United States.

Liquidia Technologies

Series C in 2010
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Luqa Pharmaceuticals

Series A in 2015
Luqa Pharmaceuticals is a China-focused company. We acquire, develop and commercialize innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline.

Semios

Private Placement in 2020
Semios specializes in providing crop management solutions for the agricultural industry. It offers a proprietary system of in-crop wireless networks coupled with remote sensors, pest monitoring, and variable rate biological pest control. This information is provided to the grower in an interface that allows the grower to reduce agricultural inputs and increase the quality of the crop produced. The company was founded in 2010 and is headquartered in Vancouver, British Columbia.

Ins Health

Angel Round in 2018
Yingshi Health is a full-process one-stop technology platform for health insurance product innovation through the establishment of a health insurance micro-ecology - PUMCH model, the ecological content includes Product product innovation services, Underwriting online intelligent underwriting, Medical medical management, Claim online intelligent claims, Health management Five parts. It has led the innovation of mid-end medical insurance, million medical insurance, elderly cancer prevention insurance, and patient medical insurance in the industry.

Cheyipai

Series C in 2014
Cheyipai is a private company engaged in e-commerce. It provides sells used vehicles online and online-to-offline (O2O) e-commerce model for the complete transaction process. Wang Tiezhong and Yang Xuejian founded Cheyipai in 2009, with its headquarters in Beijing in China. It operates as a subsidiary of Souche.com as of April 3, 2018.

Kaiheikeji Digital

Private Placement in 2018
online game sparring service platform ,Users can post demands on the platform and indicate their own level, demand and price, and then qualified players selectively take orders and accompany the clients on playing games.
Beijing Shangpin Bezi EC Co.,ltd offers online retail of fashion goods. Its merchandise mix is composed of brands such as Lanvin, Diesel, MCM, and Juicy Couture. Beijing Shangpin Bezi EC Co.,ltd was founded in 2010 and is based in Beijing, China.

Mohalla Tech Pvt. Ltd.

Private Placement in 2018
Mohalla Tech Pvt. Ltd. owns and operates social network platform ShareChat. It helps users to create and find content in preferred language and share on mobile messaging platforms. Mohalla Tech Pvt. Ltd. was incorporated in 2015 and is based in Bengaluru, India.

Keep

Series D in 2018
Keep is a young team that loves sports and is also a group of Geeks who pursue the ultimate experience. They focus on application development in the field of mobile sports, advocate the spirit of open sharing, do not imitate, do not follow suit, and only do cool products. In the age of their lives, the fitness culture is awakening, there should be more professional tools, a more pure community, and make the body easier. This is what Keep is doing. They hope that through technology-driven, more people will love fitness and enjoy sports.

Redcore Times

Series C in 2018
By 2013, more people will be using their mobile devices than PCs to get online. As your prospect customers are browsing the Internet on the go with their iPhone, Android, iPad, etc, are you getting ready to keep up with the mobile trend and give your customers a wonderful mobile experience? Now we are on the mission to help you create your custom website to perfect people's mobile browsing experience across platforms and locations.

Black Fish

Series A in 2018
Black Fish develops and operates an Internet finance platform. It provides consumer finance services such as, credit, money management, loans, and installment payment plans. Black Fish also offers financial services like consumer loans, installment, and wealth management facilities. It began operation in 2017, with its headquarters in Nanjing in China.

Snowball Finance

Series C in 2014
Snowball Finance is an internet financial information service provider that is focused on investment solutions. Snowball Finance's investment and communication platform xueqiu.com provides investors with cross-market and cross-species data query, newsletter subscriptions, and interactive communication services. These services have covered the A shares, the Hong Kong stocks, and the U.S. stock market. In addition, Snowball Finance also owns iMeigu (imeigu.com), which serves American stock investors in China.
Shanghai Celstar Bio-Pharmaceutical Holding Co., Ltd. engages in the development of drugs to treat cancer, neural and contagious diseases. The company was founded in 2001 and is based in Shanghai, China. Shanghai Celstar Bio-Pharmaceutical Holding Co., Ltd. operates as a subsidiary of Jiangsu Yueda Group Co., Ltd.

Vaccine Technologies, Inc.

Vaccine Technologies, Inc. develops and offers vaccine technology platform and related products. The company provides Hepatitis B vaccination based on a novel method of antigen presentation. The company was incorporated in 2003 and is based in Boston, Massachusetts.
Applied Optoelectronics, Inc. designs, manufactures, and sells various fiber-optic networking products worldwide. It offers optical modules, lasers, transmitters and transceivers, and turn-key equipment, as well as headend, node, and distribution equipment. The company sells its products to internet data center operators, cable television and telecommunications equipment manufacturers, and internet service providers through its direct and indirect sales channels. Applied Optoelectronics, Inc. was founded in 1997 and is headquartered in Sugar Land, Texas.

Soul

Series A in 2017
SOUL is a social network that uses AI to help users find their soul mates.

Pony.ai

Private Placement in 2020
Pony.ai, Inc. develops artificial intelligence software for autonomous mobility deployment used for manufacturing automated vehicles. It also offers public-facing Robotaxi service. The company was founded in 2016 and is based in Fremont, California with additional offices in San Francisco, California; and Beijing and Guangzhou, China.

Yunhu Health

Private Placement in 2019
Hangzhou Yunhu Technology Group Co.,Ltd develops an Internet platform for primary medical services in China. It offers a series of platform-based testing products; and a SaaS based LIS\HIS platform, designed for local medication institutions. It also provides a third party cold chain logistic services to support the blood and drug delivery. The company was founded in 2017 and is based in Hangzhou, China.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

GalaxySpace

Series A in 2018
GalaxySpace develops and builds LEO broadband satellite constellation, and 5G communication network. The company’s satellite applications include monitoring of airport, parking, and oil reserves, as well as assess land types and uses. GalaxySpace was founded in 2016 and is based in Haidian, China.